Hims & Hers stock has risen by 20% after announcing a partnership to sell the popular weight-loss drug Wegovy.

Hims & Hers on Tuesday announced a collaboration with drugmaker Novo Nordisk to bundle Wegovy and a Hims & Hers membership on ...

Hims & Hers Health, Inc.'s subscriber growth, Novo Nordisk partnership, and FDA pill approval could boost financials. Click ...

Key Takeaways Hims & Hers Health shares surged Tuesday as the company announced a partnership with Danish drugmaker Novo ...

Hims & Hers Health, Inc.'s Q1 results show 111% growth, yet shares fell 8%. Click for a look at the impact of drug access, ...

Hims & Hers Health Inc. posted better-than-expected first-quarter revenue as the company pivots away from making copycat ...

Him & Hers Health and Novo Nordisk are collaborating to offer weight-loss treatment, including access to Wegovy along with ...

Shares in Hims & Hers Health soared in early-morning trading after it announced a partnership with Wegovy maker Novo Nordisk.

Hims & Hers Health Inc. soared after Novo Nordisk A/S said it would sell its popular weight-loss drug Wegovy for a steeply ...

Health and wellness company, which sold alternatives to weight-loss drugs like Wegovy, is now collaborating with Wegovy-maker ...

The company reported adjusted earnings per share of $0.28 on revenue of $586 million – a significant rise compared to last ...

The drugmaker is racing to capture more patients now that many compounding pharmacies are restricted from making Wegovy ...